Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors.

Pérez-Martínez A, de Prada Vicente I, Fernández L, González-Vicent M, Valentín J, Martín R, Maxwell H, Sevilla J, Vicario JL, Díaz MÁ.

Exp Hematol. 2012 Nov;40(11):882-891.e1. doi: 10.1016/j.exphem.2012.07.004. Epub 2012 Jul 4.

PMID:
22771496
2.

Medulloblastoma.

von Hoff K, Rutkowski S.

Curr Treat Options Neurol. 2012 Aug;14(4):416-26. doi: 10.1007/s11940-012-0183-8.

PMID:
22622599
3.

Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell.

Bae DS, Hwang YK, Lee JK.

Cell Immunol. 2012 Mar-Apr;276(1-2):122-7. doi: 10.1016/j.cellimm.2012.04.011. Epub 2012 May 3.

PMID:
22613008
4.

The molecular classification of medulloblastoma: driving the next generation clinical trials.

Leary SE, Olson JM.

Curr Opin Pediatr. 2012 Feb;24(1):33-9. doi: 10.1097/MOP.0b013e32834ec106. Review.

5.

Medulloblasoma: challenges for effective immunotherapy.

Sonabend AM, Ogden AT, Maier LM, Anderson DE, Canoll P, Bruce JN, Anderson RC.

J Neurooncol. 2012 May;108(1):1-10. doi: 10.1007/s11060-011-0776-1. Epub 2011 Dec 16. Review.

PMID:
22173741
6.

Use of allogeneic NK cells for cancer immunotherapy.

Geller MA, Miller JS.

Immunotherapy. 2011 Dec;3(12):1445-59. doi: 10.2217/imt.11.131. Review.

7.

Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection.

Chang YT, Wu CC, Shyr YM, Chen TC, Hwang TL, Yeh TS, Chang KP, Liu HP, Liu YL, Tsai MH, Chang YS, Yu JS.

PLoS One. 2011;6(5):e20029. doi: 10.1371/journal.pone.0020029. Epub 2011 May 20.

8.

IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.

Kloess S, Huenecke S, Piechulek D, Esser R, Koch J, Brehm C, Soerensen J, Gardlowski T, Brinkmann A, Bader P, Passweg J, Klingebiel T, Schwabe D, Koehl U.

Eur J Immunol. 2010 Nov;40(11):3255-67. doi: 10.1002/eji.201040568. Epub 2010 Oct 27.

9.

Characterization of signaling function and expression of HLA class I molecules in medulloblastoma.

Smith C, Santi M, Rushing EJ, Cornelison R, MacDonald TJ, Vukmanovic S.

J Neurooncol. 2011 Jun;103(2):197-206. doi: 10.1007/s11060-010-0378-3. Epub 2010 Sep 2.

10.

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D.

Clin Cancer Res. 2010 Aug 1;16(15):3901-9. doi: 10.1158/1078-0432.CCR-10-0735. Epub 2010 Jun 11.

11.

Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma.

Huse JT, Holland EC.

Nat Rev Cancer. 2010 May;10(5):319-31. doi: 10.1038/nrc2818. Review.

PMID:
20414201
12.

A novel role of HLA class I in the pathology of medulloblastoma.

Smith C, Santi M, Rajan B, Rushing EJ, Choi MR, Rood BR, Cornelison R, MacDonald TJ, Vukmanovic S.

J Transl Med. 2009 Jul 12;7:59. doi: 10.1186/1479-5876-7-59.

13.

High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome.

Butturini AM, Jacob M, Aguajo J, Vander-Walde NA, Villablanca J, Jubran R, Erdreich-Epstein A, Marachelian A, Dhall G, Finlay JL.

Cancer. 2009 Jul 1;115(13):2956-63. doi: 10.1002/cncr.24341.

14.

NKG2D ligands expression and NKG2D-mediated cytotoxicity in human laryngeal squamous carcinoma cells.

Chen XM, Xu XQ, Sun K, Hallett WH, Zhao JD, Zhang DL.

Scand J Immunol. 2008 May;67(5):441-7. doi: 10.1111/j.1365-3083.2008.02086.x. Epub 2008 Feb 27.

15.

Medulloblastoma: from molecular pathology to therapy.

Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A.

Clin Cancer Res. 2008 Feb 15;14(4):971-6. doi: 10.1158/1078-0432.CCR-07-2072. Review.

16.

A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.

Fouladi M, Nicholson HS, Zhou T, Laningham F, Helton KJ, Holmes E, Cohen K, Speights RA, Wright J, Pollack IF; Children's Oncology Group.

Cancer. 2007 Dec 1;110(11):2535-41.

17.

Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity.

Castriconi R, Dondero A, Negri F, Bellora F, Nozza P, Carnemolla B, Raso A, Moretta L, Moretta A, Bottino C.

Eur J Immunol. 2007 Nov;37(11):3190-6.

18.

Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma.

Raffaghello L, Nozza P, Morandi F, Camoriano M, Wang X, Garrè ML, Cama A, Basso G, Ferrone S, Gambini C, Pistoia V.

Cancer Res. 2007 Jun 1;67(11):5471-8.

19.

High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors.

Pérez-Martínez A, Quintero V, Vicent MG, Sevilla J, Díaz MA, Madero L.

J Neurooncol. 2004 Mar-Apr;67(1-2):101-6.

PMID:
15072454
20.

Supplemental Content

Support Center